Athanasia Papadopoulou

My scientific journey began with a Diploma Thesis at the University of Thessaly, where I explored SNP associations in interleukin genes among Greek patients with systemic sclerosis, bridging the fields of immunogenetics and autoimmune disease. I learned various techniques, such as DNA extraction, PCR, and DNA sequencing. 

This foundational experience was followed by an internship at Utrecht University, where I investigated targeted cancer therapies through nanobody-targeted photodynamic therapy for feline oral carcinoma, trying to optimize the conjugation strategies for a more effective treatment. My work there deepened my understanding of immune response modulation against cancer cells.

I further honed my skills during my postgraduate studies in forensic biology at the University of Strathclyde, which solidified my commitment to a laboratory-based scientific career. Subsequently, as an Associate Scientist at Merck Life Sciences, I refined my cell culture expertise, adhering to rigorous laboratory practices.

My passion for research led me to Glasgow Caledonian University, where I contributed to a project on macrophage-driven resistance in Acute Myeloid Leukemia (AML). This work, published in HemaSphere and presented at the European Hematology Association Congress, highlighted the intersection of immunology and oncology in my research.

Throughout these diverse experiences, I discovered and deepened my passion for research in immunology, particularly in understanding and ultimately tackling autoimmune diseases. In my current role at the Francis Crick Institute, I am committed to further advancing our understanding of immune mechanisms and contributing to the development of innovative therapeutic strategies.